Ivonescimab (PD‑1/VEGF bispecific) Plus Chemo Outperforms PD‑1+Chemo in First‑Line Advanced Squamous NSCLC: HARMONi‑6 Results Redefine a Tough Indication
Phase 3 HARMONi‑6: ivonescimab + paclitaxel/carboplatin increased median PFS to 11.1 vs 6.9 months (HR 0.60, P<0.0001) and improved ORR versus tislelizumab+chemo in first‑line advanced squamous NSCLC, with low major bleeding (≥ grade 3, 1.9%).